Postdoctoral position(s) available in autumn 2019 at the University of Helsinki
Our
lab studies mitochondrial morphogenesis and dynamics. More
specifically, we focus on the molecular mechanism of mitochondrial
membrane architectural organization and factors involved in regulation
of mitochondrial shape, dynamics, and their functional link to
mitochondrial diseases.
We
are looking for highly motivated individual(s) with a strong background
in cell biology/mitochondrial biology, and biochemistry.
For more information, please refer to the relevant publication:
Wang L, Yan Z, Vihinen H, Eriksson O, Wang W, Soliymani R, Lu Y, Xue Y, Jokitalo E, Li J, Zhao H* (2018) FAM92A1 Is a BAR Domain
Protein Required for Mitochondrial Ultrastructure and Function. J. Cell Biol. 218:97-111.
Please
send a cover letter with short description of your research interests
and previous experience, current CV, and names of three
references to Hongxia.zhao@helsinki.fi .
Orion Corporation is a globally operating Finnish
pharmaceutical company – a builder of well-being. Orion develops,
manufactures and markets human and veterinary pharmaceuticals and active
pharmaceutical ingredients.
Description of position
We are building up the Rare Diseases Therapy Area and
are looking for an enthusiastic and innovative scientist who can
contribute with strong disease biology knowledge in the field of rare
genetic disorders (or neurodegerative disorders). Your main
responsibilities will be to:
Actively contribute to project ideation, planning and execution of research activities.
Provide expertise in molecular biology and drug mechanism of action.
Perform
hands-on laboratory work related to transcription and translation of
e.g. lysosomal and mitochondrial proteins as well as to cell signaling
pathways, and how these can be targeted and modified.
Analyse and interpret data and effectively document and communicate results.
Interface with external academic, biotechnology, and contract research organizations.
Description of the unit
The focus of our Rare Diseases Therapy Area is on
progressive, serious and life-threatening diseases, where patients are
lacking adequate treatment. We aim to develop treatments which are
disease modifying or which deliver significant symptomatic relief to
patients. To fulfill this exciting task the Rare Diseases Therapy area
is strengthened by recruiting new R&D experts to our team in Turku.
The therapy area is newly established and you have a great opportunity
to be part of developing our processes.Therapy area of the Central
Nervous System (CNS) is accountable for the research and development of
medications for neurodegenerative diseases (NDD).
We offer
We offer exciting opportunities to create and have an impact to the future therapies for patients.
In Orion we have a highly interesting R&D pipeline and
enthusiastic working environment with opportunities to use your own
strengths to build your competence development and career. As an expert
of your own field you will be a member of multi-disciplinary team
jointly innovating and developing new treatments for the patients.
Appreciation of colleagues and continuous development are part of our
core values. The culture of Orion R&D is informal and we enjoy
working together.
We are passionate about the patient welfare and serve as The
Voice of Science and the Patient – if this inspires you too – join us!
Requirements
Ph.D. degree in cell and/or molecular biology with at least 3 years postdoc experience.
Hands-on
experience with molecular biology techniques such as qPCR, WB, siRNA,
CRISPR/Cas9 as well as immunodetection techniques.
Expertise in cell signaling.
Expertise in rare genetic disorders or neurodegenerative diseases research.
Understanding of drug discovery and development.
Contact information
Would you like to know more about the position? Please
contact Harry Björklund, Research Director Rare Diseases, +358509667436.
He is best available during the following times (EEST): Monday 20th of
May 14.00 – 16.00, Wednesday 22nd of May 9.00 – 11.00 and Tuesday 28th
of May 14.00 – 16.00. Please send your application latest on 2 June
2019.
Orion Corporation operates in more than 25 countries, where we
Orionees, 3200 in total, work in all kinds of positions. We encourage
people to develop their competences, and offer opportunities to affect
own job description and create own career path at Orion.
Orion Corporation is a globally operating Finnish
pharmaceutical company – a builder of well-being. Orion develops,
manufactures and markets human and veterinary pharmaceuticals and active
pharmaceutical ingredients.
Description of position
As a member of the newly established Biologics and New
modalities Discovery Groups you will work closely with cross-functional
teams to provide computational biology support to the antibody and new
modalities discovery process. Your primary responsibilities will include
the application of structural analysis to sequences from both internal
and public databases to enable therapeutic protein design,
oligonucleotide designs, gene editing designs, CRISPR-based gene
editing, and antibody repertoire analysis.
The identification of relevant liabilities in nucleotide
sequences will be a critical responsibility in order to successfully
support generation and optimization of the modalities (therapeutic
oligonucleotide, peptides and biologics). You support day to day
laboratory work in-house and you will therefore have a good possibility
to do a lot of hands-on laboratory work verifying the computational
designs. You will be also the primary contact with collaborations with
partners and CROs on your expertise areas. You will be based in Turku.
We offer
Exciting opportunities to create and have an impact to the future therapies for patients.
In
Orion we have a highly interesting R&D pipeline and enthusiastic
working environment with opportunities to use your own strengths to
build your competence development and career. As an expert of your own
field you will be a member of multi-disciplinary team jointly innovating
and developing new treatments for the patients. Appreciation of
colleagues and continuous development are part of our core values. The
culture of Orion R&D is informal and we enjoy working together.
We are passionate about the patient welfare and serve as The
Voice of Science and the Patient – if this inspires you too – join us!
Description of the unit
Orion’s pharmaceutical innovations are created within
its R&D organization, including e.g. non-clinical research, clinical
development, formulation development and medical affairs. The
organization employs top professionals in the field of drug molecule
development and optimization.
The newly established Biologics and New Modalities team is part
of our R&D organization and it is responsible for bringing as new
treatment modalities for Orion’s pipeline covering therapeutic
nucleotides, delivery technologies and gene therapy. Adding the
possibility to modulate the target with either small or large molecules
enables us to choose the right target and then use the best modalities
to modulate the target protein in order to create the best value for
patients. To fulfill this exciting task the New Modalities function is
strengthened by recruiting new R&D experts with a track record of on
advanced therapy modalities. The function is currently to set up and
you have a great opportunity to be part of developing our processes.
Requirements
To operate successfully in this position you should
have a PhD degree in genetics, molecular biology, computational or
biology structural biology with several years of post-doctoral
experience in computational biology to support optimization of
therapeutic large molecules. You should also have thorough understanding
of in vitro models for system biology and biophysical data analysis.
Willingness to create new things is a must because you will
join a team that is just recently set up. The role includes
collaboration within Orion and with various collaborators, therefore
strong communication skills and an ability to convince your audience is
an asset.
Contact information
Would you like to know more about the position? Please
contact Jyrki Lehtimäki, Senior Manager, Strategic Development,
+358509667478. He is best available during the following times (Finnish
times): 17th and 24th May 15.00-17.00 pm. Please send your application
latest on 2 June 2019.
Orion Corporation is a globally operating Finnish
pharmaceutical company – a builder of well-being. Orion develops,
manufactures and markets human and veterinary pharmaceuticals and active
pharmaceutical ingredients.
Description of position
We are building up the Rare Diseases Therapy Area and
are looking for an enthusiastic and innovative scientist who can
contribute with strong disease biology knowledge in the field of rare
genetic disorders (or neurodegerative disorders). Your main
responsibilities will be to:
Actively contribute to project ideation, planning and execution of research activities.
Develop methodologies and set up in vitro and in vivo disease
models for rare diseases as well as validate the models against each
other and against pathology observed in rare diseases patients.
Contribute to phenotyping behavior, performance and disease progression in in vivo disease models.
Plan, conduct and supervise experimental treatment studies in vitro and in vivo disease models.
Analyse and interpret data and effectively document and communicate results.
Interface with external academic, biotechnology, and contract research organizations.
Description of unit
The focus of our Rare Diseases Therapy Area is on
progressive, serious and life-threatening diseases, where patients are
lacking adequate treatment.We aim to develop
treatments which are disease modifying or which deliver significant
symptomatic relief to patients. To fulfill this exciting task the Rare
Diseases Therapy area is strengthened by recruiting new R&D experts
to our team in Turku. The therapy area is newly established and you have
a great opportunity to be part of developing our processes.Therapy area
of the Central Nervous System (CNS) is accountable for the research and
development of medications for neurodegenerative diseases (NDD).
We offer
We offer exciting opportunities to create and have an impact to the future therapies for patients.
In Orion we have a highly interesting R&D pipeline and
enthusiastic working environment with opportunities to use your own
strengths to build your competence development and career. As an expert
of your own field you will be a member of multi-disciplinary team
jointly innovating and developing new treatments for the patients.
Appreciation of colleagues and continuous development are part of our
core values. The culture of Orion R&D is informal and we enjoy
working together.
We are passionate about the patient welfare and serve as The
Voice of Science and the Patient – if this inspires you too – join us!
Requirements
Ph.D. degree in relevant field of life sciences and at least 3 years postdoc experience.
Experience in cell and molecular biology techniques.
Experience in cell culture techniques.
Experience in in vivo behavioural and performance models.
Experience in genetically modified in vivo disease models.
Experience in rare genetic disorders or neurodegenerative diseases research.
Understanding of drug discovery and development.
Contact information
Would you like to know more about the position? Please
contact Harry Björklund, Research Director Rare Diseases, +358509667436.
He is best available during the following times (EEST): Monday 20th of
May 14.00 – 16.00, Wednesday 22nd of May 9.00 – 11.00 and Tuesday 28th
of May 14.00 – 16.00. Please send your application latest on 2 June
2019.
Orion Corporation operates in more than 25 countries, where we
Orionees, 3200 in total, work in all kinds of positions. We encourage
people to develop their competences, and offer opportunities to affect
own job description and create own career path at Orion.
Lääkealan turvallisuus- ja kehittämiskeskus Fimea on
sosiaali- ja terveysministeriön alainen virasto, joka valvoo ja kehittää
lääkealaa väestön terveydeksi.
Work tasks
Lääkehoitojen arviointi -prosessin tehtävinä on kehittää
lääkealaa sekä koota, tuottaa, arvioida ja välittää tutkimukseen
perustuvaa riippumatonta lääketietoa väestölle, sosiaali- ja
terveydenhuollon ammattilaisille sekä julkisen päätöksenteon tarpeisiin.
Tarkemmin: https://www.fimea.fi/kehittaminen_ja_HTA/
Tehtävä tarjoaa aitiopaikan lääkkeiden järkevän käytön edistämiseen
ja lääkehuollon kehittämiseen muuttuvassa sosiaali- ja terveydenhuollon
palvelujärjestelmässä.
Qualifications
Hakijalta odotamme
– soveltuvaa ylempää korkeakoulututkintoa
– aikaisempaa kokemusta soveltavasta tutkimustyöstä
– kykyä tiimityöskentelyyn
– sujuvia vuorovaikutus- ja esiintymistaitoja
– hyvää englannin kielen suullista ja kirjallista taitoa
– matkustusvalmiutta kotimaassa
Aikaisempi kokemus kyselytutkimuksen suunnittelusta, toteutuksesta ja raportoinnista sekä tutkijakoulutus katsotaan eduksi.
Hyvä ruotsin kielen taito on eduksi tehtävän hoitamisessa.
Other language skills
Hyvä englannin kielen suullinen ja kirjallinen taito.
Scope of employment
Form of employment:
Temporary employment
Scope:
Office work
Commencement:
01/08/2019
Tai sopimuksen mukaan. Virkaan nimitettävälle voidaan määrätä enintään kuuden kuukauden koeaika.
You may also apply for this position by
submitting your application to the address below. The job reference of
the role must be cited both in the actual application and on the
envelope. Applications will not be returned.
Lääkealan turvallisuus- ja kehittämiskeskus/Kirjaamo
PL 55
00034 FIMEA
Salary
Lääkehoitojen
arviointi -prosessin tutkijan määräaikainen virkasuhde on sijoitettu
vaativuusluokkaan 8-9, jossa tehtäväkohtainen palkanosa on 3132,61 –
3454,71 euroa/kk. Lisäksi maksetaan henkilökohtaiseen työsuoritukseen
perustuvaa palkanosaa, joka on enintään 42 % tehtäväkohtaisesta
palkanosasta (uudella henkilöllä yleensä välillä 8-21 % riippuen
henkilön osaamisesta ja työkokemuksesta).
Employment
Number of positions advertised:
1
Contact
Contact persons
Pertti Happonen
Johtaja
+358 29 522 3510
Hanna-Mari Jauhonen
Tutkijalääkäri
+35829 5223512
Placement
Lääkealan turvallisuus- ja kehittämiskeskus Fimea/ Helsinki
Mannerheimintie 103b
00280
Helsinki
or
Lääkealan turvallisuus- ja kehittämiskeskus Fimea/ Kuopio
Microkatu 1
70210
Kuopio
or
Lääkealan turvallisuus- ja kehittämiskeskus Fimea/Tampere
Biokatu 10
33520
Tampere
or
Lääkealan turvallisuus- ja kehittämiskeskus Fimea/Turku
Itsenäisyydenaukio 2
20800
Turku
Other
Fimea toimii monipaikkaisena virastona. Fimean
toimipaikat ovat Kuopiossa, Helsingissä, Turussa ja Tampereella.
Tehtävän sijoituspaikka voidaan sopia.
SLU seeks a highly motivated researcher for a 2 year
post-doc in food microstructures. The position has its base at the
Department of Molecular Sciences, the food science unit. The department
generates and conveys vital information about
food composition and properties and its importance to our health. This
is done in close collaboration with other researchers and stakeholders
in the food chain, nationally and internationally. The department offers
a creative and stimulating international environment,
and is part of Uppsala BioCenter, a strong research environment for
basic and applied research.
The research and education focuses on food
composition and follows the food chain via preparation and processing of
the raw materials. The composition, quality (sensory, health, safety)
and functionality of food are considered in relation
to primary production, processing for the interests of the individual
consumer. The microstructure is affected by the physical and chemical
environments and processing conditions. In this work the impact of
microstructure on quality properties such as texture,
barrier and release properties, etc. is of interest.
We welcome your application no later than 2019-06-24.
Position as researcher at Department of Molecular Sciences
SLU has as one of its strategic goals to develop
circular bio-based economics and efficient use of renewable raw
materials. The Department of Molecular Sciences at SLU, where the
employment is located, currently consists of approximately
110 employees and together with two other Departments forms an inspiring
research environment at BioCentrum in Uppsala with expertise in plant
biology, mycology, plant pathology, microbiology, food science,
computational genetics, chemistry and biotechnology.
It provides a high quality infrastructure including consisting of plant
cultivation facilities, advanced microscopy and molecular biology, X-ray
and NMR. The Department provides the scientific community, trustee and
the public with knowledge about chemical
compounds and biological processes, as well as their importance to
society and its development. The department conducts research, teaching
and environmental monitoring in the field of inorganic, physical and
organic chemistry, biochemistry, natural product
chemistry, food science and microbiology. Visit us at https://www.slu.se/institutions/molekylara-vetenskaper/
SLU is looking for a highly motivated researcher for a biomaterial and
food development focusing on how microstructures affect physical
properties. Development towards a sustainable society requires new
methods of producing materials and food. The position
is located at the Department of Molecular Sciences. We generate and
convey important information about the composition and properties of
food and biomaterials. The department is involved in teaching at
Bachelor’s as well as Master’s levels. The courses range
from food science and food technology to basic chemistry.
We welcome your application no later than 2019-05-24.
Senior Scientist, In Vitro and In Vivo Disease Models (Turku)
Orion
Corporation is a globally operating Finnish pharmaceutical company – a
builder of well-being. Orion develops, manufactures and markets human
and veterinary pharmaceuticals and active pharmaceutical ingredients.
Description of position
We are building up the
Rare Diseases Therapy Area and are looking for an enthusiastic and
innovative scientist who can contribute with strong disease biology
knowledge in the field of rare genetic disorders
(or neurodegerative disorders). Your main responsibilities will be to:
Actively contribute to project ideation, planning and execution of research activities.
Develop methodologies and set up in vitro and in vivo disease models for rare diseases as well as validate the models against each other
and against pathology observed in rare diseases patients.
Contribute to phenotyping behavior, performance and disease progression in in vivo disease models.
Plan, conduct and supervise experimental treatment studies in vitro and in vivo disease models.
Analyse and interpret data and effectively document and communicate results.
Interface with external academic, biotechnology, and contract research organizations.
Requirements
Ph.D. degree in relevant field of life sciences and at least 3 years postdoc experience.
Experience in cell and molecular biology techniques.
Experience in cell culture techniques.
Experience in in vivo behavioural and performance models.
Experience in genetically modified in vivo disease models.
Experience in rare genetic disorders or neurodegenerative diseases research.
Description of position
We are building up the Rare Diseases Therapy Area and are looking for an
enthusiastic and innovative scientist who can contribute with strong
disease biology knowledge in the field of rare genetic disorders (or
neurodegerative disorders). Your main responsibilities
will be to:
Actively contribute to project ideation, planning and execution of research activities.
Provide expertise in molecular biology and drug mechanism of action.
Perform
hands-on laboratory work related to transcription and translation of
e.g. lysosomal and mitochondrial proteins as well as to cell signaling
pathways, and how these can be targeted and modified.
Analyse and interpret data and effectively document and communicate results.
Interface with external academic, biotechnology, and contract research organizations.
Requirements
Ph.D. degree in cell and/or molecular biology with at least 3 years postdoc experience.
Hands-on
experience with molecular biology techniques such as qPCR, WB, siRNA,
CRISPR/Cas9 as well as immunodetection techniques.
Expertise in cell signaling.
Expertise in rare genetic disorders or neurodegenerative diseases research.
Saammeko esitellä ensimmäisen, uudistuneen Solubiologi-lehden! Uusi taittajamme Joanna Pylvänäinen on tehnyt erinomaista työtä! Joannan portfolioon voi käydä tutustumassa osoitteessa: http://www.imagenis.fi/en/about/
Haemme Helsinkiin HUSLAB: iin Meilahden patologian laboratorioon sijaista
erikoistuvan sairaalasolubiologin vakanssiin 6kk ajaksi (1.6-31.12.2019).
Paikka tullaan täyttämään
nopealla aikataululla, joten jos olet kiinnostunut ilmaise se sähköpostilla kummallekin sairaalasolubiologeistamme:
olayinka.raheem@hus.fi ja mia.kero@hus.fi.
Tiedustelut ainoastaan sähköpostitse. Eduksi katsotaan solubiologian
pääaineopinnot. Hakija voi olla valmistunut tai juuri valmistumassa
oleva henkilö. Ennen valintaa pidetään sopiviksi katsomillemme
henkilöille lyhyt haastattelu.
Place: Auditorium SN200, Snellmania, Yliopistonranta 1 E, Kuopio
Credit points: 1-3 (1 for attendance at lectures
both days, 2 for attendance at the lectures both days and demos or
poster, 3 for attendance at the lectures both days, demos and poster)
Course directors: Anna-Liisa Levonen, Kirsi Ketola, Leena Latonen
Organizing Units: A.I. Virtanen Institute for
Molecular Sciences & Institute of Biomedicine at the University of
Eastern Finland
Course description:
This course will present state-of-the-art methods
and science in cancer research. The course consists of two days of
seminars, a poster session, and a demo day for live-cell imaging and
analysis with the IncuCyte S3 cell imager. The goal
of this course is to gain a wide overview of current methods in cancer
research introduced by top-level cancer researchers nationally and
internationally. The demo day will introduce students to IncuCyte S3 and
its novel applications.
The course includes a range of aspects from
molecular, cellular and tissue level research to whole organism disease
modelling. The latest techniques, analysis methods and bioinformatics
related to cellular, tissue, high throughput, sequencing
and imaging technologies are introduced. The methods are presented in
the contexts of real-life research questions and project. While geared
towards cancer, the techniques introduced in this course are applicable
to other research fields as well.
Lectures are open to all students, postdocs and
personnel. Maximum participant amount to the lectures is 150. For demos
maximum participant amount is 40.
Registration:
Registration is free of charge for all the participants.
